Project Grant R41GM165099
Award Date 9/16/25
Completion Date 9/15/26
Dollars Obligated $350K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Middletown, DE, USA
Similar Awards
- This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research by Function Therapeutics Inc. to investigate the use of a new class of small molecule compounds called Parmodulins for the treatment of neuropathic pain. The $499,863 award, granted on September 11, 2025, will fund research to synthesize and test various Parmodulins for their ability to modulate the...
- The Project Grant award of $675,107 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to develop novel non-opioid, non-addictive analgesics for treating neuropathic pain. The project, led by Northeastern University, will focus on designing and evaluating "dualsteric modulators" that act as both cannabinoid CB1 receptor...
- This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to develop GPR139 antagonists for the treatment of pain. The $603,406 award to Research Triangle Institute (RTI International) aims to optimize the potency, selectivity, and drug-like properties of GPR139 antagonists through medicinal chemistry, and then evaluate...
- This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...
- This $4,039,366 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), will support a research project titled "A Fully Humanized Functional Genomic Screen to Identify and Validate Pain Therapeutic Targets" under the NIH's Drug Use and Addiction Research Programs (CFDA 93.279). The project will leverage innovative CRISPR-based screening and human dorsal root ganglion (DRG) transcriptomic data to...
- This federal Project Grant award for $667,349.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant program. The award is supporting research conducted by the University of Pennsylvania to investigate the role of endogenous opioid signaling and neural circuits involved in modulating pain perception and placebo analgesia. The research aims to elucidate the...
- This federal Project Grant award of $118,457.00 from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), is funded under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports research by Dr. Sylvanus Toikumo at the University of Pennsylvania to characterize the genetic architecture underlying chronic pain and addiction, with the goal of informing the development of non-addictive analgesic medications. The project aims to leverage...
- This federal Project Grant award of $453,062.00 was provided by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports research to better understand the cellular mechanisms regulating opioid receptor signaling and the development of pharmacological tolerance, which is a critical challenge in the clinical management of opioid-based pain treatments. The research aims to...
- This Project Grant award of $398,137 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for developing high-precision epigenetic therapeutics to address the growing opioid use disorder (OUD) epidemic in the United States. The award will enable Boston Interactome LLC to apply a novel approach targeting protein-protein interactions of the neuronal G9A complex, a key regulator of DFosB expression under chronic opioid exposure....